{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:48:27Z","timestamp":1793832507563,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT03798535"],"award-info":[{"award-number":["NCT03798535"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jtho.2022.10.003","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T01:30:05Z","timestamp":1666661405000},"page":"181-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":239,"title":["Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.M.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sibille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilde D.","family":"Haakensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Markman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Jeroen N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Licour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.10.003_bib1","unstructured":"Royal College of Physicians. NLCA annual report (for the 2018 audit period), version 2. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/annual-report-version-2-published-march-2021. Accessed January 28, 2022."},{"issue":"suppl 23","key":"10.1016\/j.jtho.2022.10.003_bib2","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1002\/cncr.29045","article-title":"Analysis of stage and clinical\/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jtho.2022.10.003_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib5","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12885-020-06734-3","article-title":"Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis","volume":"20","author":"Hansen","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable Stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib8","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.07.3569","article-title":"Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B","volume":"25","author":"Vokes","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib10","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","article-title":"Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology","volume":"26","author":"Hanna","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib11","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized Phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable Stage III non-small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","article-title":"GILT\u2013A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer","volume":"192","author":"Flentje","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.jtho.2022.10.003_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.003_bib15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2022.10.003_bib16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2022.10.003_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","article-title":"Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study","volume":"20","author":"Hui","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC-update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC-an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of Stage III non\u2013small-cell lung cancer: ASCO Guideline","volume":"40","author":"Daly","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib24","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib25","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jtho.2021.05.003","article-title":"Real-world treatment patterns and clinical outcomes in patients with\u00a0Stage III NSCLC: results of KINDLE, a multicountry observational study","volume":"16","author":"Jazieh","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib26","doi-asserted-by":"crossref","first-page":"190024","DOI":"10.1183\/16000617.0024-2019","article-title":"Interdisciplinary multimodality management of stage III nonsmall cell lung cancer","volume":"28","author":"Huber","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtho.2022.10.003_bib27","doi-asserted-by":"crossref","first-page":"S738","DOI":"10.1016\/S1556-0864(21)01921-3","article-title":"79MO PACIFIC-R: real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy","volume":"16","author":"McDonald","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.jtho.2022.10.003_bib28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10637-021-01091-9","article-title":"Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients","volume":"39","author":"Taugner","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2022.10.003_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib32","doi-asserted-by":"crossref","first-page":"744956","DOI":"10.3389\/fonc.2021.744956","article-title":"A\u00a0real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer","volume":"11","author":"Bruni","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib33","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/j.ijrobp.2021.07.1242","article-title":"Real-world outcomes of chemoradiation and consolidative durvalumab in unresectable stage III non-small-cell lung cancer \u2014 a systematic review","volume":"111","author":"Hu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2022.10.003_bib34","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1002\/cam4.3306","article-title":"Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: the SOLUTION study","volume":"9","author":"Horinouchi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2022.10.003_bib35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cllc.2021.05.009","article-title":"Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable Stage III non-small-cell lung cancer (PACIFIC)","volume":"22","author":"Socinski","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib37","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jtho.2022.10.003_bib38","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","author":"O\u2019Rourke","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2022.10.003_bib39","first-page":"495","article-title":"Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer","volume":"26","author":"El-Sharouni","year":"2006","journal-title":"Anticancer Res"},{"issue":"suppl 4","key":"10.1016\/j.jtho.2022.10.003_bib40","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib41","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.2014.59.2360","article-title":"Definitive and adjuvant radiotherapy in locally advanced non\u2013small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"33","author":"Bezjak","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib42","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib43","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2022.10.003_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtho.2022.10.003_bib45","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.10.003_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2020.11.024","article-title":"Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC)","volume":"151","author":"Faivre-Finn","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.10.003_bib48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s43018-020-0074-y","article-title":"The impact of the COVID-19 pandemic on cancer care","volume":"1","author":"Richards","year":"2020","journal-title":"Nat Cancer"},{"issue":"suppl 9","key":"10.1016\/j.jtho.2022.10.003_bib49","doi-asserted-by":"crossref","first-page":"ix113","DOI":"10.1093\/annonc\/mdz438.021","article-title":"PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2022.10.003_bib50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.21037\/tlcr-20-608","volume":"9","author":"Zhou","year":"2020","journal-title":"Transl Lung Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422018536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422018536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:50:15Z","timestamp":1761562215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422018536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1556086422018536"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.10.003","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}